Association between vaginal microbiota and vaginal inflammatory immune markers in postmenopausal women
- 7 May 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Menopause
- Vol. 31 (7) , 575-581
Abstract
Objective: In premenopausal individuals, vaginal microbiota diversity and lack of Lactobacillus dominance are associated with greater mucosal inflammation, which is linked to a higher risk of cervical dysplasia and infections. It is not known if the association between the vaginal microbiota and inflammation is present after menopause, when the vaginal microbiota is generally higher-diversity and fewer people have Lactobacillus dominance. Methods: This is a post hoc analysis of a subset of postmenopausal individuals enrolled in a randomized trial for treatment of moderate-severe vulvovaginal discomfort that compared vaginal moisturizer, estradiol, or placebo. Vaginal fluid samples from 0, 4, and 12 weeks were characterized using 16S rRNA gene sequencing (microbiota) and MesoScale Discovery (vaginal fluid immune markers: IL-1b, IL-1a, IL-2, IL-6, IL-18, IL-10, IL-9, IL-13, IL-8, IP10, MIP1a, MIP1b, MIP3a). Global associations between cytokines and microbiota (assessed by relative abundance of individual taxa and Shannon index for alpha, or community, diversity) were explored, adjusting for treatment arm, using linear mixed models, principal component analysis, and Generalized Linear Mixed Model + Microbiome Regression-based Kernel Association Test (GLMM-MiRKAT). Results: A total of 119 individuals with mean age of 61 years were included. At baseline, 29.5% of participants had a Lactobacillus-dominant vaginal microbiota. Across all timepoints, alpha diversity (Shannon index, P = 0.003) was highly associated with immune markers. Individual markers that were associated with Lactobacillus dominance were similar to those observed in premenopausal people: IL-10, IL-1b, IL-6, IL-8 (false discovery rate [FDR] < 0.01), IL-13 (FDR = 0.02), and IL-2 (FDR = 0.09). Over 12 weeks, change in alpha diversity was associated with change in cytokine concentration (Shannon, P = 0.018), with decreased proinflammatory cytokine concentrations observed with decreasing alpha diversity. Conclusions: In this cohort of postmenopausal individuals, Lactobacillus dominance and lower alpha diversity were associated with lower concentrations of inflammatory immune markers, as has been reported in premenopausal people. This suggests that after menopause lactobacilli continue to have beneficial effects on vaginal immune homeostasis, despite lower prevalence.Keywords
This publication has 28 references indexed in Scilit:
- Impact of Topical Interventions on the Vaginal Microbiota and Metabolome in Postmenopausal WomenJAMA Network Open, 2022
- Association between postmenopausal vulvovaginal discomfort, vaginal microbiota, and mucosal inflammationAmerican Journal of Obstetrics and Gynecology, 2021
- Bacterial vaginosis and its association with infertility, endometritis, and pelvic inflammatory diseaseAmerican Journal of Obstetrics and Gynecology, 2021
- Vaginal estrogen therapy is associated with increased Lactobacillus in the urine of postmenopausal women with overactive bladder symptomsAmerican Journal of Obstetrics and Gynecology, 2020
- The vaginal microbiota and its association with human papillomavirus, Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium infections: a systematic review and meta-analysisClinical Microbiology and Infection, 2019
- Cervicovaginal Microbiota and Reproductive Health: The Virtue of SimplicityCell Host & Microbe, 2018
- Reduced levels of genital tract immune biomarkers in postmenopausal women: implications for HIV acquisitionAmerican Journal of Obstetrics and Gynecology, 2016
- Cervicovaginal Bacteria Are a Major Modulator of Host Inflammatory Responses in the Female Genital TractImmunity, 2015
- Testing in Microbiome-Profiling Studies with MiRKAT, the Microbiome Regression-Based Kernel Association TestThe American Journal of Human Genetics, 2015
- A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseasesAmerican Journal of Obstetrics and Gynecology, 2007